Lipid Disorders
Feature
Patients complain some obesity care startups offer pills, and not much else
A wave of startups offer access to a new category of weight-loss drugs coupled with intensive behavioral coaching online. But already concerns are...
Conference Coverage
Tirzepatide cuts BP during obesity treatment
“The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term benefits of [tirzepatide] on...
Conference Coverage
Statins boost glycemia slightly, but CVD benefits prevail
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
Conference Coverage
New dual-agonist weight-loss injection impressive, but early days
The “bottom line” is that this potential new antiobesity/diabetes drug is “very promising, but [it is] still a little early to say where it...
Conference Coverage
Tirzepatide lowers weight across all groups with obesity
The antiobesity medication semaglutide “took things up one big notch, and now tirzepatide is up a little notch above that,” one expert said.
Conference Coverage
Dietary supplements hyped as LDL cholesterol lowering are a bust: SPORT
The list of supplements without effects on LDL in the placebo-controlled trial include commercial preparations of fish oil, cinnamon, garlic,...
Conference Coverage
New trial suggests CV benefit with EPA: RESPECT-EPA
The open-label trial could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose...
Conference Coverage
Precision CAD testing shows 70% cut in composite risk at 1 year
A streamlined protocol for evaluating suspected stable chest pain substantially improved outcomes at 1 year in the PRECISE trial.
Conference Coverage
ISCHEMIA-EXTEND: Conservative stable CAD management holds up
The ISCHEMIA trial results showed equipoise between conservative and invasive management of stable CAD. Extended follow-up strengthened the...
Conference Coverage
Diuretic agents equal to prevent CV events in hypertension: DCP
Cardiovascular events were nearly identical with two different hypertension drugs in the randomized Diuretic Comparison Project trial.
Conference Coverage
Triglyceride-lowering fails to show CV benefit in large fibrate trial
In the phase 3 PROMINENT trial, pemafibrate improved multiple lipid fractions in patients with type 2 diabetes, without any impact on...